Full- versus Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study
Seminars in Thrombosis and Hemostasis · 13.07.2026
DOI: 10.1055/a-2904-5824 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 13.07.2026. Verfasst von Paolo Santini und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Thrombosis Unit, Department of Geriatric, Orthopedic, an….
Abstract (Originalsprache)
AbstractExtended anticoagulation is recommended in subjects with cancer-associated thrombosis (CT). The API-CT trial showed that reduced-dose apixaban is noninferior to full dose for preventing recurrent venous thromboembolism (VTE), but the generalizability of these findings to real-world populations remains to be determined. We conducted a multicenter retrospective cohort study including patients with CT receiving extended direct oral anticoagulants (DOACs) at full or reduced dose, after at least 6 months of anticoagulation. The primary efficacy outcome was recurrent VTE. The primary safety outcome was major bleeding (MB) and clinically relevant nonmajor bleeding (CRNMB). A total of 603 patients were included, of whom 381 (63.2%) received reduced-dose and 222 (36.8%) full-dose DOACs. During a median follow-up of 335 days, recurrent VTE occurred in 3.9% of patients in the reduced-dose and 2.7% in the full-dose group (p = 0.4). MB occurred in 1.0 and 0.9% (p = 0.9) and CRNMB in 4.7 and 5.4% (p = 0.7), respectively. In adjusted analyses, reduced-dose DOACs were associated with a nonsignificant increase in VTE recurrence (hazard ratio: 1.4, 95% confidence interval: 0.5–3.7), with no differences in bleeding outcomes. In this multicenter real-world cohort, reduced-dose DOACs were associated with low rates of recurrent VTE and bleeding, comparable to those observed with full-dose regimens. These findings suggest that reduced-dose anticoagulation may be a feasible option in selected patients with CT requiring extended treatment, supporting individualized decision-making. Further studies are needed to better define optimal dose selection in this setting.
Autor:innen und Institutionen
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Thrombosis Unit, Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Italy.
- Sapienza University of Rome, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Italy.
- University of Insubria, Department of Medicine and Surgery, Italy.
- S. Giacomo Apostolo Hospital, Department of Vascular Medicine, Italy.
- University of Padua, Department of Medicine, Italy.
ORCID-Profile: Paolo Santini, Davide Santagata, Carolina Mosoni, Angelo Porfidia, Lorenza Bertù, Tatiana Scandiuzzi Piovesan, Danilo Menichelli, Pasquale Pignatelli, Adriana Visonà, Marco Paolo Donadini, Walter Ageno, Roberto Pola
Zitieren
APA
Santini, P., Santagata, D., Mosoni, C., Mancinetti, F., Porfidia, A., Bertù, L., Zurlo, C., Scandiuzzi Piovesan, T., Menichelli, D., Pignatelli, P., Visonà, A., Donadini, M. P., Ageno, W., & Pola, R. (2026). Full- versus Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/a-2904-5824
Vancouver
Santini P, Santagata D, Mosoni C, Mancinetti F, Porfidia A, Bertù L, et al. Full- versus Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study. Seminars in Thrombosis and Hemostasis. 2026. doi:10.1055/a-2904-5824
BibTeX
@article{Santini2026,
author = {Santini, Paolo and Santagata, Davide and Mosoni, Carolina and Mancinetti, Francesco and Porfidia, Angelo and Bertù, Lorenza and Zurlo, Chiara and Scandiuzzi Piovesan, Tatiana and Menichelli, Danilo and Pignatelli, Pasquale and Visonà, Adriana and Donadini, Marco Paolo and Ageno, Walter and Pola, Roberto},
title = {Full- versus Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
doi = {10.1055/a-2904-5824}
}
EUVIMED